Boundless Bio Inc
Research Boundless Bio Inc (BOLD) on Bullrun: market cap USD 55.04M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBOLD
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 55.04M
- Financial periodFY2025
- Net income-USD 58.20M
- Free cash flow-USD 47.21M
Valuation Snapshot
latest market cap is USD 55.04M.
About Boundless Bio Inc
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.
Frequently asked questions
What is Boundless Bio Inc's market cap?
Boundless Bio Inc's market capitalization is USD 55.04M.
What does Boundless Bio Inc do?
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers.